[外周动脉闭塞性疾病中动脉内和静脉内输注前列腺素E1的风险效益分析]
[Risk-benefit analysis of intra-arterial and intravenous PGE1 infusions in peripheral arterial occlusive disorders].
作者信息
Heidrich H
机构信息
Franziskus-Krankenhaus Berlin.
出版信息
Vasa Suppl. 1991;33:346-7.
PMID:1788752
Abstract
On the basis of pharmacological and clinical studies this review describes the effects of prostaglandin E1 (PGE1) on the cardiopulmonary system and its profile of adverse reactions taking into account spontaneous reports of side effects. All in all no increased risk of cardiovascular adverse reactions was obvious. PGE1 rather showed some desirable effects on heart and lung. Thus the analysis revealed a positive risk benefit relation for PGE1, provided that dosage and contra-indications are not neglected.
摘要
基于药理学和临床研究，本综述描述了前列腺素E1（PGE1）对心肺系统的作用及其不良反应特征，同时考虑了副作用的自发报告。总体而言，心血管不良反应风险并未明显增加。PGE1对心脏和肺部反而显示出一些有益作用。因此，分析表明，只要不忽视剂量和禁忌证，PGE1具有良好的风险效益关系。
相似文献
1
2
3
[Prostaglandin E1 in therapy of peripheral arterial occlusive disease].[前列腺素E1在外周动脉闭塞性疾病治疗中的应用]
Wien Klin Wochenschr. 1991;103(18):558-65.
4
[Mechanisms of action of prostaglandin E1 in therapy of peripheral arterial occlusive diseases].
Vasa. 2003 Nov;32(4):187-92. doi: 10.1024/0301-1526.32.4.187.
5
6
7
8
[Pharmacologic concepts for clinical use of prostaglandin E1].[前列腺素E1临床应用的药理学概念]
Vasa Suppl. 1991;33:335-6.
9
[Prostaglandin E1 in intermittent claudication].[前列腺素E1与间歇性跛行]
Vasa Suppl. 1992;35:147-8.
Zotero 插件